» Articles » PMID: 20717171

Further Delineation of the Phenotype of Severe Congenital Neutropenia Type 4 Due to Mutations in G6PC3

Overview
Journal Eur J Hum Genet
Specialty Genetics
Date 2010 Aug 19
PMID 20717171
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Severe congenital neutropenia type 4 (SCN4) is an autosomal recessive condition, which was defined recently with identification of the causative mutations in G6PC3. To date there are only three reports in the literature describing patients with SCN4 with mutations in the G6PC3 gene. We report four individuals with SCN4 who belong to a single large consanguineous kindred. We provide an overview of the non-haematological features of the condition with a focus on the adult phenotype, which has not been previously described in detail. We show that the superficial venous changes seen in SCN4 patients can develop into varicose veins and venous ulcers in adulthood. We review the range of congenital anomalies associated with SCN4. We demonstrate that secundum atrial septal defect, patent ductus arteriosus and valvular defects are the most frequent cardiac anomalies in SCN4. Drawing parallels with type 1 glycogen storage disease, we propose that poor growth of prenatal onset, mild-to-moderate learning disability, primary pulmonary hypertension, delayed or incomplete puberty, hypothyroidism and dysmorphism likely represent features of this syndrome. We also suggest monitoring for lipid anomalies, and kidney and liver function in affected patients. Delineation of the SCN4 phenotype may help in appropriate treatment and management and provide further insights into the pathogenesis of this multisystem disease.

Citing Articles

neuronal Glucose-6-Phosphatase is a modulator of neuropeptide release that regulates muscle glycogen stores via FMRFamide signaling.

Miyamoto T, Hedjazi S, Miyamoto C, Amrein H Proc Natl Acad Sci U S A. 2024; 121(30):e2319958121.

PMID: 39008673 PMC: 11287260. DOI: 10.1073/pnas.2319958121.


Severe congenital neutropenia due to G6PC3 deficiency: early and delayed phenotype of a patient.

Moradian N, Zoghi S, Rayzan E, Seyedpour S, Heredia R, Boztug K Allergy Asthma Clin Immunol. 2023; 19(1):51.

PMID: 37296469 PMC: 10257254. DOI: 10.1186/s13223-023-00804-4.


Novel variants in a patient with glycogen storage disease type IIIb and pulmonary hypertension caused by pulmonary veno-occlusive disease: A case report.

Shindo A, Ueda K, Minatsuki S, Nakayama Y, Hatsuse S, Fujita K Front Genet. 2023; 14:1148067.

PMID: 37035733 PMC: 10078958. DOI: 10.3389/fgene.2023.1148067.


Mechanisms of Lower Extremity Vein Dysfunction in Chronic Venous Disease and Implications in Management of Varicose Veins.

Raffetto J, Khalil R Vessel Plus. 2021; 5.

PMID: 34250453 PMC: 8270011. DOI: 10.20517/2574-1209.2021.16.


Hypothesis: A Novel Neuroprotective Role for Glucose-6-phosphatase (G6PC3) in Brain-To Maintain Energy-Dependent Functions Including Cognitive Processes.

Dienel G Neurochem Res. 2020; 45(11):2529-2552.

PMID: 32815045 DOI: 10.1007/s11064-020-03113-z.


References
1.
Xia J, Bolyard A, Rodger E, Stein S, Aprikyan A, Dale D . Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol. 2009; 147(4):535-42. PMC: 2783282. DOI: 10.1111/j.1365-2141.2009.07888.x. View

2.
Hutton J, OBrien R . Glucose-6-phosphatase catalytic subunit gene family. J Biol Chem. 2009; 284(43):29241-5. PMC: 2785553. DOI: 10.1074/jbc.R109.025544. View

3.
Janecke A, Mayatepek E, Utermann G . Molecular genetics of type 1 glycogen storage disease. Mol Genet Metab. 2001; 73(2):117-25. DOI: 10.1006/mgme.2001.3179. View

4.
Arostegui J, Sanchez de Toledo J, Pascal M, Garcia C, Yague J, Diaz de Heredia C . A novel G6PC3 homozygous 1-bp deletion as a cause of severe congenital neutropenia. Blood. 2009; 114(8):1718-9. DOI: 10.1182/blood-2009-04-219451. View

5.
Humbert M, Labrune P, Simonneau G . Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr. 2002; 161 Suppl 1:S93-6. DOI: 10.1007/s00431-002-1012-y. View